Nevanac Pregnancy Warnings
Use is not recommended.
AU TGA pregnancy category: C
US FDA pregnancy category: C
Comments:
-This drug should not be used by women of child bearing potential not using contraception.
-Use of this drug during late pregnancy should be avoided because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (e.g., premature closure of ductus arteriosus).
Animal studies have revealed evidence of malformations, postimplantation losses, decreased fetal weight/growth, and lower fetal survival at maternotoxic doses. There are no adequate and well-controlled studies in pregnant women.
AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
See references
